Genetic variants in m6A regulator genes confer susceptibility and progression of HCC in a Northern Chinese population.

m6A 调节基因的遗传变异与中国北方人群中肝细胞癌的易感性和进展有关

阅读:7
作者:Ji Guohua, Gao Cize, Yang Yi, Ding Yuli, Liu Ruining, Wu Shuang, Zhang Xuelong, Liang Xiao, Fu Songbin, Cui Xiaobo
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally. While m6A regulators are implicated in cancer progression, the role of single nucleotide polymorphisms (SNPs) in m6A regulator genes in HCC susceptibility remains underexplored. Here, we evaluated 31 candidate SNPs across eight dysregulated m6A regulator genes in a case-control study comprising 800 HCC patients and 800 healthy controls from Northeast China. Genotyping revealed three SNPs significantly associated with elevated HCC risk: rs2736158 C allele (PRRC2A; adjusted odds ratio [OR] = 1.295, 95% [CI] = 1.039-1.615, p = 0.021), rs9366785 A allele (PRRC2A; adjusted odds ratio [OR] = 1.312, 95% [CI] = 1.011-1.704, p = 0.041), and rs274054 C allele (IGF2BP3; adjusted odds ratio [OR] = 1.224, 95% [CI] = 1.040-1.440, p = 0.015). Comparison of genotype frequency of three SNPs under given genetic models further linked rs274054 CC (IGF2BP3), rs2736158 CC (PRRC2A), and rs9366785 AA + AG (PRRC2A) genotypes to higher HCC risk. Subgroup analyses identified associations between specific genotypes (e.g., rs9906944 TT/TC in IGF2BP1) and adverse clinicopathological features, including vascular invasion and liver cirrhosis. Haplotype analysis highlighted the CACA haplotype (PRRC2A: rs280801, rs2736171, rs2736158, rs2736157) as a high-susceptibility marker (adjusted odds ratio [OR] = 1.297, 95% [CI] = 1.041-1.616, p = 0.020). Our findings suggest that m6A regulator SNPs contribute to HCC susceptibility and progression, offering insights into genetic biomarkers for risk stratification in Northeast Chinese populations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。